|
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 19.47% | Shs Outstand | 18.24M | Perf Week | 12.34% |
| Market Cap | 335.46M | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 0.94M | Perf Month | - |
| Income | - | PEG | - | EPS next Q | - | Inst Own | - | Short Float | - | Perf Quarter | - |
| Sales | - | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | - | Perf Half Y | - |
| Book/sh | - | P/B | - | EPS next Y | - | ROA | - | Target Price | - | Perf Year | - |
| Cash/sh | - | P/C | - | EPS next 5Y | - | ROE | - | 52W Range | 14.31 - 23.90 | Perf YTD | 16.39% |
| Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -23.05% | Beta | - |
| Dividend % | - | Quick Ratio | - | Sales past 5Y | - | Gross Margin | - | 52W Low | 28.56% | ATR | 1.89 |
| Employees | - | Current Ratio | - | Sales Q/Q | - | Oper. Margin | - | RSI (14) | - | Volatility | 7.45% - |
| Optionable | No | Debt/Eq | - | EPS Q/Q | - | Profit Margin | - | Rel Volume | 0.21 | Prev Close | 16.67 |
| Shortable | Yes | LT Debt/Eq | - | Earnings | - | Payout | - | Avg Volume | 668.73K | Price | 18.39 |
| Recom | - | SMA20 | 12.86% | SMA50 | 12.86% | SMA200 | 12.86% | Volume | 139,533 | Change | 10.32% |
 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite